Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evan C Chen

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Bone Marrow Transplantation|October 25, 2024
Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemiaGege Gui, Niveditha Ravindra, Pranay S Hegde, et al.
Blood Advances|February 24, 2026
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapseH Moses Murdock, Haesook T Kim, Katie Maurer, et al.
Blood Advances|October 31, 2025
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapseH Moses Murdock, Haesook T Kim, Katie Maurer, et al.
Haematologica|April 2, 2026
Hypomethylating agents plus venetoclax <i>versus</i> intensive chemotherapy prior to transplant in high-risk acute myeloid leukemiaGuillaume Berton, Jan Philipp Bewersdorf, Julia Gilhodes, et al.
Blood Advances|January 26, 2026
Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic TransplantationLuis E Aguirre, Haesook T Kim, Hany Elmariah, et al.
Blood Advances|March 24, 2025
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapyHannah Lust, Liora M Schultz, Soyang Kwon, et al.
Blood Advances|October 6, 2025
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemiaYannis K Valtis, Chenyu Lin, David Nemirovsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2024
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALLGregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, et al.
Blood|February 5, 2026
Blinatumomab Nonresponse Correlates with Poor Survival After BrexucabtageneHrishikesh Krishna Srinagesh, Vishal K Gupta, Amy Zhang, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Bone Marrow Transplantation|October 25, 2024
Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemiaGege Gui, Niveditha Ravindra, Pranay S Hegde, et al.
Blood Advances|February 24, 2026
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapseH Moses Murdock, Haesook T Kim, Katie Maurer, et al.
Blood Advances|October 31, 2025
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapseH Moses Murdock, Haesook T Kim, Katie Maurer, et al.
Haematologica|April 2, 2026
Hypomethylating agents plus venetoclax <i>versus</i> intensive chemotherapy prior to transplant in high-risk acute myeloid leukemiaGuillaume Berton, Jan Philipp Bewersdorf, Julia Gilhodes, et al.
Blood Advances|January 26, 2026
Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic TransplantationLuis E Aguirre, Haesook T Kim, Hany Elmariah, et al.
Blood Advances|March 24, 2025
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapyHannah Lust, Liora M Schultz, Soyang Kwon, et al.
Blood Advances|October 6, 2025
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemiaYannis K Valtis, Chenyu Lin, David Nemirovsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2024
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALLGregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, et al.
Blood|February 5, 2026
Blinatumomab Nonresponse Correlates with Poor Survival After BrexucabtageneHrishikesh Krishna Srinagesh, Vishal K Gupta, Amy Zhang, et al.
Pageof 5